We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sorafenib: Tolerance in Patients on Chronic Hemodialysis.
- Authors
Rey, Pablo Maroto; Villavicencio, Humberto
- Abstract
Background/Objective: Improved understanding of renal cell carcinomas (RCC) and recent contributions in the field of RCC biology led to the development of a novel class of drugs, i.e. multiple-kinase inhibitors, targeting growth factor receptors (e.g. sorafenib). Sorafenib has proven significant benefit in terms of progression-free survival in a phase II trial in RCC patients. A subsequent randomized phase III study (Treatment Approaches in Renal Cancer Global Evaluation Trial) confirmed the significantly prolonged progression-free survival and improvement in the quality of life compared to patients receiving placebo. In the USA and Europe, sorafenib has been approved for the treatment of advanced RCC. Patients: Two RCC patients on chronic hemodialysis were treated with sorafenib. Results: Both patients responded to sorafenib treatment. Apart from high blood pressure, a major adverse effect of sorafenib treatment, treatment was well tolerated, in agreement with previous results. Conclusion: The results of our study confirm the beneficial effect of sorafenib in the treatment of RCC in our 2 patients on dialysis. Copyright © 2008 S. Karger AG, Basel
- Subjects
RENAL cell carcinoma; DRUG tolerance; HEMODIALYSIS; CELL receptors; PROTEIN kinases
- Publication
Oncology, 2008, Vol 74, Issue 3/4, p245
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000151394